These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
96 related articles for article (PubMed ID: 20054640)
1. Concordance of HER2 in primary tumor and leptomeningeal metastases: now what? Lin NU Breast Cancer Res Treat; 2010 Aug; 123(1):129-31. PubMed ID: 20054640 [No Abstract] [Full Text] [Related]
2. Concordant HER2 status between metastatic breast cancer cells in CSF and primary breast cancer tissue. Park IH; Kwon Y; Ro JY; Lee KS; Ro J Breast Cancer Res Treat; 2010 Aug; 123(1):125-8. PubMed ID: 19916047 [TBL] [Abstract][Full Text] [Related]
3. Molecular profiling of tumor cells in cerebrospinal fluid and matched primary tumors from metastatic breast cancer patients with leptomeningeal carcinomatosis. Magbanua MJ; Melisko M; Roy R; Sosa EV; Hauranieh L; Kablanian A; Eisenbud LE; Ryazantsev A; Au A; Scott JH; Park JW Cancer Res; 2013 Dec; 73(23):7134-43. PubMed ID: 24142343 [TBL] [Abstract][Full Text] [Related]
4. Cerebrospinal fluid cytology diagnosis of HER2-positive leptomeningeal carcinomatosis from HER2-positive metastatic gastric cancer: case report. Cavanna L; Rocchi A; Gorgni S; Ambroggi M; Foroni RP; Ubbiali A; Civardi G J Clin Oncol; 2011 May; 29(13):e367-8. PubMed ID: 21300922 [No Abstract] [Full Text] [Related]
5. Leptomeningeal carcinomatosis: easy to miss. Sekhar A; Corbo B; Das K; Biswas S J R Coll Physicians Edinb; 2017 Dec; 47(4):351-352. PubMed ID: 29537406 [TBL] [Abstract][Full Text] [Related]
6. Intratumoral heterogeneity of HER2/neu in breast cancer--a rare event. Hanna W; Nofech-Mozes S; Kahn HJ Breast J; 2007; 13(2):122-9. PubMed ID: 17319852 [TBL] [Abstract][Full Text] [Related]
7. Diagnosis of leptomeningeal metastasis without a history of malignancy in the absence of cerebrospinal fluid abnormalities. Yokote A; Kawamoto T; Namioka T; Moteki Y; Kawamata T Clin Neurol Neurosurg; 2014 Apr; 119():88-90. PubMed ID: 24635933 [No Abstract] [Full Text] [Related]
8. HER2 gene status in primary breast cancers and matched distant metastases. Tapia C; Savic S; Wagner U; Schönegg R; Novotny H; Grilli B; Herzog M; Barascud AD; Zlobec I; Cathomas G; Terracciano L; Feichter G; Bubendorf L Breast Cancer Res; 2007; 9(3):R31. PubMed ID: 17511881 [TBL] [Abstract][Full Text] [Related]
9. Carcinomatous infiltration of cerebrospinal fluid with reactive lymphocytosis and granulocytosis. Anoop P; Saso R; Atra A Am J Hematol; 2010 Oct; 85(10):791. PubMed ID: 20196167 [No Abstract] [Full Text] [Related]
10. Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients. Pestrin M; Bessi S; Galardi F; Truglia M; Biggeri A; Biagioni C; Cappadona S; Biganzoli L; Giannini A; Di Leo A Breast Cancer Res Treat; 2009 Dec; 118(3):523-30. PubMed ID: 19597704 [TBL] [Abstract][Full Text] [Related]
11. A misleading case of CSF cytology: a cautionary tale. Parker T; Mahoney C; Pencharz D; Cwynarski K; Liu R Pract Neurol; 2014 Dec; 14(6):429-31. PubMed ID: 24713142 [No Abstract] [Full Text] [Related]
12. Molecular detection of human mammaglobin in cerebrospinal fluid from breast cancer patient with leptomeningeal carcinomatosis. Dono M; Ferro P; Benedetti L; Capellini C; Moroni M; Dessanti P; Bacigalupo B; Tartaglione A; Battolla E; Fedeli F; Roncella S J Neurooncol; 2009 Feb; 91(3):295-8. PubMed ID: 18841443 [TBL] [Abstract][Full Text] [Related]
13. Preservation of HER2/neu gene during evolution: possible physiological role and survival advantages. Kurbel S; Dmitrović B; Golcić G; Dovhanj J Med Hypotheses; 2006; 66(5):1039-40. PubMed ID: 16446054 [No Abstract] [Full Text] [Related]
14. Expression and amplification of Her2, EGFR and cyclin D1 in breast cancer: immunohistochemistry and chromogenic in situ hybridization. Cho EY; Choi YL; Han JJ; Kim KM; Oh YL Pathol Int; 2008 Jan; 58(1):17-25. PubMed ID: 18067636 [TBL] [Abstract][Full Text] [Related]
15. Autocrine GMCSF Signaling Contributes to Growth of HER2 Ansari KI; Bhan A; Saotome M; Tyagi A; De Kumar B; Chen C; Takaku M; Jandial R Cancer Res; 2021 Sep; 81(18):4723-4735. PubMed ID: 34247146 [TBL] [Abstract][Full Text] [Related]
16. How to do it: how to get the most out of cerebrospinal fluid cytology. Milburn-McNulty P; Michael B; Moxham N; Fletcher N; Crooks D Pract Neurol; 2012 Aug; 12(4):241-3. PubMed ID: 22869767 [No Abstract] [Full Text] [Related]
17. Analysis of the HER2/neu gene amplification in microdissected breast cancer tumour samples. Seth RM; Burger AM; Kahn HJ Anticancer Res; 2006; 26(2A):927-31. PubMed ID: 16619488 [TBL] [Abstract][Full Text] [Related]
18. HER2 testing: a review of detection methodologies and their clinical performance. Laudadio J; Quigley DI; Tubbs R; Wolff DJ Expert Rev Mol Diagn; 2007 Jan; 7(1):53-64. PubMed ID: 17187484 [TBL] [Abstract][Full Text] [Related]
19. Polyclonal antibodies against gp185HER2 peptides: their putative role in the identification of a particular HER2 status in patients with breast cancer. Di Modugno F; Buglioni S; Mottolese M; Bello DD; Cascioli S; Chersi A; Santoni A; Nisticò P J Immunother; 2001; 24(3):221-31. PubMed ID: 11394499 [TBL] [Abstract][Full Text] [Related]
20. Leptomeningeal metastases from prostate cancer: an emerging clinical conundrum. Orphanos G; Ardavanis A Clin Exp Metastasis; 2010; 27(1):19-23. PubMed ID: 19904616 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]